MOUNT THOM N.S. – It’s a cold and wet day when Karen Kittilsen Levine packs up and heads over Mount Thom to Pictou County.
In her vehicle are needles, water, alcohol swabs and condoms. For most people, it is not your typical collection of supplies for a road trip, but for Levine it is something she packs each week as drives across Northern Nova Scotia to help people who are finding it difficult to help themselves.
As program co-ordinator for Northern Healthy Connections Society, Levine visits Pictou County to distribute new supplies to people with drug addictions.
MISSISSAUGA, ON , March 14, 2018 /CNW/ – In support of Canada’s commitment to the World Health Organization’s (WHO) goal of eliminating chronic hepatitis C infection by 2030, Gilead Sciences Canada, Inc. ( Gilead Canada ) today announced a series of grants to support screening and linkage to care projects across Canada. These initiatives will focus on hepatitis C screening within high-risk patient populations and linking diagnosed patients to care. In total, 13 Hepatitis C Micro-Elimination Grants have been awarded to projects to be conducted among targeted high-risk populations including immigrants, prisoners, First Nations, people with HIV infection, and people who inject drugs.
” Gilead Canada recognizes that it will take more than science to eliminate the burden of hepatitis C on patients, our health system and Canadian society as a whole,” said Kennet Brysting, General Manager of Gilead Canada . “Together with our grant recipients, all of whom have a record of excellence in their work and are leaders in their fields, we can take collective steps to help work towards the realization of the WHO goal of hepatitis C elimination by 2030 right here in Canada .”
ANY British Columbian living with chronic hepatitis C now is able to access treatment, regardless of the severity of their disease, Health Minister Adrian Dix announced on Tuesday.
In addition to expanding coverage to all British Columbians, a new chronic hepatitis C drug has been added to the PharmaCare formulary.
“In years past, a hepatitis C diagnosis was a stressful and lifelong struggle,” said Dix. “I’m pleased to share that, as of today, anyone in B.C. living with this now-curable virus will have a choice of several treatment options – all of which are fully funded under PharmaCare.”
TORONTO, March 1, 2018 /CNW/ – An estimated eight million Canadians may be affected by liver disease, an illness that exhibits little to no symptoms, involves everyone from newborns to seniors, and is rarely tested by doctors during annual checkups.
Recent indicators gathered by the Canadian Liver Foundation (CLF) show that an increased prevalence of liver diseases including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B & C, and liver cancer are why in just ten years, the statistic that was once 1 in 10, is now 1 in 4.
“The reason we are seeing this increase in liver disease is partially due to lifestyle choices we don’t always associate with causing us a tremendous amount of harm,” says Gary Fagan, President of the CLF. “From supersizing your meal, to binge-watching a television series, these ordinary activities can seriously compromise the well-being of your liver.”
TORONTO, Feb. 6, 2018 /CNW/ – The Canadian Treatment Action Council (CTAC) has published a white paper entitled, “The time has come to eliminate hepatitis C in Canada,” which summarizes the increasing gaps in Canada’s response to the hepatitis C epidemic and identifies seven calls-to-action. CTAC is once again demonstrating its commitment to securing and ensuring access to testing, treatment, care and support for Canadians living with HIV and hepatitis C virus (HCV).
Along with like-minded allies, CTAC is calling upon policymakers and community leaders to respect their engagement to eliminate hepatitis C infection in Canada by adopting a public health strategy and making a clear commitment toward the elimination of viral hepatitis. Commenting on the campaign, CTAC Executive Director Shelina Karmali said, “We’re hoping our white paper stimulates a response at all levels of government so that every Canadian managing HCV will have access to equitable and timely testing and treatment.” Ms. Karmali added, “HCV is 100 per cent curable.”
The Issues An estimated 220,000 – 245,000 Canadians are infected with HCV. Unfortunately, around 44% of those individuals are unaware of their status, and are often only diagnosed incidentally to something else. There is a large population of individuals currently aging with HCV, whether diagnosed or not, who are now experiencing complications of HCV, some of which are quite severe, such as cirrhosis, liver failure and death. The cost to the healthcare system is greater than treating HCV. Indigenous communities, people who inject drugs, ethno-cultural communities and baby boomers are at an increased risk of being affected by HCV.
The administrators of a class action settlement for people infected with hepatitis C during Canada’s tainted blood scandal are appealing for people who missed a deadline for compensation to come forward and make a claim.
Thousands of Canadians were infected with the liver disease after receiving tainted blood transfusions or blood products between 1986 and 1990.
Under a class-action settlement approved by the courts in 1999, potential claimants to compensation were given a deadline of June 30, 2010 to file a claim.
– New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for
Chronic Hepatitis C Virus Infection –
MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ – Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labeling of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV-1. Health Canada granted EPCLUSA an NOC in July 2016, for the treatment of adults with genotype 1-6 chronic HCV infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis in combination with ribavirin.
“HCV co-infection remains a major cause of morbidity in HIV-infected individuals. With this expanded indication, EPCLUSA provides co-infected patients with a much-needed one-pill-a-day regimen that works across all HCV genotypes and at all stages of disease. Being compatible with most widely-used antiretroviral regimens adds to its convenience,” said Dr. Brian Conway, President and Medical Director, Vancouver Infectious Diseases Centre. “With EPCLUSA, physicians have an important new treatment option for their HCV/HIV co-infected patients.”